永安药业
(002365)
| 流通市值：17.66亿 | | | 总市值：21.31亿 |
| 流通股本：2.44亿 | | | 总股本：2.95亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 972,890,144.84 | 802,818,715.84 | 578,438,052.77 | 311,166,729.63 |
| 营业收入 | 972,890,144.84 | 802,818,715.84 | 578,438,052.77 | 311,166,729.63 |
| 二、营业总成本 | 965,619,212.39 | 766,377,535.34 | 531,246,790 | 309,419,184.44 |
| 营业成本 | 721,213,010.48 | 557,367,835.63 | 391,693,570.42 | 220,604,224.8 |
| 税金及附加 | 10,085,263.65 | 7,257,902.12 | 4,744,929.31 | 1,937,471.68 |
| 销售费用 | 54,500,064.25 | 60,875,072.57 | 45,494,663.74 | 40,395,430.67 |
| 管理费用 | 145,217,150.93 | 111,830,903.74 | 72,946,185.67 | 35,121,883.99 |
| 研发费用 | 41,500,983.96 | 35,948,208.66 | 22,743,920.27 | 9,951,522.52 |
| 财务费用 | -6,897,260.88 | -6,902,387.38 | -6,376,479.41 | 1,408,650.78 |
| 其中:利息费用 | 374,404.64 | 255,120.5 | 151,056.62 | 85,414.15 |
| 其中:利息收入 | 1,880,430.78 | 837,341.14 | 665,754.47 | 345,287.59 |
| 加:公允价值变动收益 | 11,825,152.12 | 10,964,337.52 | 10,879,871.11 | 6,545,418.74 |
| 加:投资收益 | 25,505,792.22 | 17,104,395.2 | 8,785,902.22 | 1,891,449.7 |
| 资产处置收益 | 45,015,736.27 | -131,421.1 | -7,881.18 | - |
| 资产减值损失(新) | -96,571,598.38 | 2,689,325.89 | 3,525,952.68 | 5,241,925.14 |
| 信用减值损失(新) | 1,762,158.53 | 991,550.79 | 979,342.35 | -1,534,999.59 |
| 其他收益 | 10,840,027.44 | 7,022,849.4 | 2,139,277.6 | 1,430,325.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 5,648,200.65 | 75,082,218.2 | 73,493,727.55 | 15,321,664.22 |
| 加:营业外收入 | 2,648,179.67 | 297,812.72 | 144,912.81 | 67,597.07 |
| 减:营业外支出 | 2,244,746.81 | 4,132,855.93 | 7,623,650.29 | 329,283.79 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 6,051,633.51 | 71,247,174.99 | 66,014,990.07 | 15,059,977.5 |
| 减:所得税费用 | 34,466,189.59 | 30,160,985.94 | 8,995,972.32 | 1,365,244.42 |
| 六、净利润 | -28,414,556.08 | 41,086,189.05 | 57,019,017.75 | 13,694,733.08 |
| 持续经营净利润 | -52,123,864.91 | 41,086,189.05 | 57,019,017.75 | 13,694,733.08 |
| 终止经营净利润 | 23,709,308.83 | - | - | - |
| 归属于母公司股东的净利润 | -12,312,563.51 | 46,427,620.9 | 56,126,324.7 | 14,983,070.77 |
| 少数股东损益 | -16,101,992.57 | -5,341,431.85 | 892,693.05 | -1,288,337.69 |
| (一)基本每股收益 | -0.04 | 0.16 | 0.19 | 0.05 |
| (二)稀释每股收益 | -0.04 | 0.16 | 0.19 | 0.05 |
| 八、其他综合收益 | 894,753.32 | 3,113,136.57 | 3,391,382.87 | -895,806.31 |
| 归属于母公司股东的其他综合收益 | 894,753.32 | 3,113,136.57 | 3,391,382.87 | -895,806.31 |
| 九、综合收益总额 | -27,519,802.76 | 44,199,325.62 | 60,410,400.62 | 12,798,926.77 |
| 归属于母公司股东的综合收益总额 | -11,417,810.19 | 49,540,757.47 | 59,517,707.57 | 14,087,264.46 |
| 归属于少数股东的综合收益总额 | -16,101,992.57 | -5,341,431.85 | 892,693.05 | -1,288,337.69 |
| 公告日期 | 2024-04-19 | 2023-10-27 | 2023-08-24 | 2023-04-28 |
| 审计意见(境内) | 标准无保留意见 | | | |